AstraZeneca in AI Collaboration With Immunai to Inform Cancer …
WEB1 day ago — (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the ...
Immunai and AstraZeneca's $18 Million AI Collaboration to …
WEB2 days ago — Immunai, an AI biotech company, has announced a multi-year collaboration with AstraZeneca. This partnership aims to enhance the development of oncology therapies through advanced data analysis. Under the terms of the agreement, AstraZeneca will provide Immunai with $18 million for the initial phase of this collaboration.
AstraZeneca extends AI immuno-oncology R&D pact with Immunai
WEB1 day ago — Through its re-upped pact with AstraZeneca, Immunai is slated to receive $18 million for the first phase of the new project. The collaboration as a whole will focus on identifying which patients ...
Israel's Immunai expands strategic tie with AstraZeneca
WEB2 days ago — The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient. Israeli company Immunai, a developer of AI-based tools for improving drug discovery processes, has announced a strategic agreement with pharmaceuticals company AstraZeneca.Immunai will receive $18 million from AstraZeneca at the initial stage of the research, but ...
Immunai, AstraZeneca collaborate to optimize cancer clinical …
WEBImmunai, known for its groundbreaking use of single-cell genomics and machine learning, has quickly become a key player in the biotech space. With a team of 170 employees, including 85 PhDs or MDs ...
Israeli AI startup forges $18m partnership with AstraZeneca for …
WEB1 day ago — Israeli-American biotech unicorn Immunai on Thursday secured a $18 million partnership to help the Anglo-Swedish pharma giant AstraZeneca improve the effectiveness and potential success rates of ...
Immunai signs $18M collaboration with AstraZeneca to make …
WEB1 day ago — AstraZeneca. Israeli startup Immunai, which has developed a system that maps the human immune system with single-cell granularity, has announced a multi-year collaboration with AstraZeneca. Under the terms of the agreement, Immunai is set to receive $18 million for the initial phase of the collaboration. The collaboration will …
AstraZeneca: collaboration with start-up Immunai on AI
WEB1 day ago — September 26, 2024 at 11:12 am EDT. Immunai announced Thursday that it has signed a multi-year collaboration agreement with AstraZeneca, which it will help to optimize its clinical trials through AI-based applications. The Israeli-born start-up, now based in New York, says the cooperation will focus on decision-making, dose selection ...
Immunai and AstraZeneca Collaborate to Optimize Oncology …
WEB2 days ago — Immunai, a New York-based AI biotech company, has entered a multi-year collaboration with AstraZeneca to optimize oncology clinical trials.This partnership will use Immunai’s proprietary AMICA platform and Immunodynamics Engine (IDE)—technologies combining multi-omic single-cell data and advanced AI models of the immune system—to improve trial design and clinical decision-making.
AstraZeneca invests $18 million in Immunai’s AI technology
WEB1 day ago — AstraZeneca has struck an $18 million deal with biotechnology firm Immunai Inc. to use its AI model of the immune system, which is intended to improve the efficiency of specific cancer drug trials. This collaboration aligns with AstraZeneca’s broader strategy to harness artificial AI for drug discovery and development, building on a previous $247 million agreement with US-based Absci to ...
- Some results have been removed